Wedbush Maintains Outperform on Tango Therapeutics, Lowers Price Target to $40
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsPrice Target
Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and lowers the price target from $45 to $40.
Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and lowers the price target from $45 to $40.